Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 118,776,632
  • Shares Outstanding, K 1,591,540
  • Annual Sales, $ 25,638 M
  • Annual Income, $ 5,953 M
  • 36-Month Beta 1.51
  • Price/Sales 4.59
  • Price/Cash Flow 13.23
  • Price/Book 23.60

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.30 +3.66%
on 07/12/17
75.04 -1.51%
on 07/21/17
+1.27 (+1.75%)
since 06/23/17
3-Month
64.61 +14.39%
on 05/17/17
75.04 -1.51%
on 07/21/17
+9.25 (+14.31%)
since 04/24/17
52-Week
55.06 +34.24%
on 10/28/16
75.04 -1.51%
on 07/21/17
+10.10 (+15.83%)
since 07/22/16

Most Recent Stories

More News
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

XLV : 80.96 (-0.04%)
VHT : 150.75 (+0.13%)
MRK : 62.57 (-0.10%)
IYH : 169.87 (+0.04%)
FHLC : 39.13 (+0.13%)
ABBV : 73.91 (-0.96%)
GILD : 74.39 (+0.85%)
AMGN : 181.06 (+0.47%)
PFE : 33.32 (-0.48%)
BMY : 55.60 (-0.09%)
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

XLV : 80.96 (-0.04%)
VHT : 150.75 (+0.13%)
MRK : 62.57 (-0.10%)
IYH : 169.87 (+0.04%)
FHLC : 39.13 (+0.13%)
ABBV : 73.91 (-0.96%)
GILD : 74.39 (+0.85%)
AMGN : 181.06 (+0.47%)
PFE : 33.32 (-0.48%)
BMY : 55.60 (-0.09%)
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

NVO : 41.90 (-2.44%)
JNJ : 133.01 (-1.70%)
ABBV : 73.91 (-0.96%)
PFE : 33.32 (-0.48%)
AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive...

ABBV : 73.91 (-0.96%)
Abbvie Inc Set to Possibly Pullback After Yesterday's Rally of 1.77%

Abbvie Inc (NYSE:ABBV) traded in a range yesterday that spanned from a low of $72.95 to a high of $74.20. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $73.47...

ABBV : 73.91 (-0.96%)
Is Gilead (GILD) Poised for a Beat This Earnings Season?

Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

VRTX : 166.11 (+1.80%)
ABBV : 73.91 (-0.96%)
GILD : 74.39 (+0.85%)
ALXN : 130.74 (-0.80%)
Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

JNJ : 133.01 (-1.70%)
ABBV : 73.91 (-0.96%)
GILD : 74.39 (+0.85%)
BMY : 55.60 (-0.09%)
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.

LLY : 84.74 (+0.09%)
ABBV : 73.91 (-0.96%)
PFE : 33.32 (-0.48%)
BIIB : 284.70 (+0.63%)
Perrigo Company Gets FDA Approval for Generic Topical Gel

Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

ENZ : 11.30 (-0.44%)
ABBV : 73.91 (-0.96%)
SNY : 47.71 (unch)
PRGO : 76.35 (+0.18%)
Repros' Proellex Stays on Partial Clinical Hold, Shares Fall

Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.

ENZ : 11.30 (-0.44%)
BAYRY : 130.1800 (+0.52%)
RPRX : 0.37 (unch)
ABBV : 73.91 (-0.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Support & Resistance

2nd Resistance Point 75.08
1st Resistance Point 74.49
Last Price 73.91
1st Support Level 73.58
2nd Support Level 73.26

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.